Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 6
2022 5
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.
Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U, Knebel F, Burmester G, Radbruch A, Mei HE, Mashreghi MF, Hiepe F, Alexander T. Ostendorf L, et al. Among authors: garantziotis p. N Engl J Med. 2020 Sep 17;383(12):1149-1155. doi: 10.1056/NEJMoa2023325. N Engl J Med. 2020. PMID: 32937047
Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis.
Frangou E, Garantziotis P, Grigoriou M, Banos A, Nikolopoulos D, Pieta A, Doumas SA, Fanouriakis A, Hatzioannou A, Manolakou T, Alissafi T, Verginis P, Athanasiadis E, Dermitzakis E, Bertsias G, Filia A, Boumpas DT. Frangou E, et al. Among authors: garantziotis p. Ann Rheum Dis. 2022 Oct;81(10):1409-1419. doi: 10.1136/annrheumdis-2021-222069. Epub 2022 Jul 29. Ann Rheum Dis. 2022. PMID: 35906002 Free PMC article.
The genomic landscape of ANCA-associated vasculitis: Distinct transcriptional signatures, molecular endotypes and comparison with systemic lupus erythematosus.
Banos A, Thomas K, Garantziotis P, Filia A, Malissovas N, Pieta A, Nikolakis D, Panagiotopoulos AG, Chalkia A, Petras D, Bertsias G, Boumpas DT, Vassilopoulos D. Banos A, et al. Among authors: garantziotis p. Front Immunol. 2023 Mar 27;14:1072598. doi: 10.3389/fimmu.2023.1072598. eCollection 2023. Front Immunol. 2023. PMID: 37051253 Free PMC article.
Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?
Nezos A, Skarlis C, Psarrou A, Markakis K, Garantziotis P, Papanikolaou A, Gravani F, Voulgarelis M, Tzioufas AG, Koutsilieris M, Moutsopoulos HM, Kotsifaki E, Mavragani CP. Nezos A, et al. Among authors: garantziotis p. Front Immunol. 2021 Jun 18;12:683623. doi: 10.3389/fimmu.2021.683623. eCollection 2021. Front Immunol. 2021. PMID: 34220834 Free PMC article.
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events.
Nikolopoulos D, Loukogiannaki C, Sentis G, Garantziotis P, Manolakou T, Kapsala N, Nikoloudaki M, Pieta A, Flouda S, Parodis I, Bertsias G, Fanouriakis A, Filia A, Boumpas DT. Nikolopoulos D, et al. Among authors: garantziotis p. Ann Rheum Dis. 2024 Apr 12:ard-2024-225664. doi: 10.1136/ard-2024-225664. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38609158 Free article.
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Fanouriakis A, Govoni M, Sidiropoulos P, Boumpas DT, Bortoluzzi A, Bertsias G. Pitsigavdaki S, et al. Among authors: garantziotis p. Ann Rheum Dis. 2024 Mar 12;83(4):464-474. doi: 10.1136/ard-2023-224919. Ann Rheum Dis. 2024. PMID: 38233103 Free PMC article.
17 results